14th World ADC London 2024 ExCeL London, London
Antibody-drug conjugates are coming of age with a remarkable surge in recent times, which has marked a turning point in their development. Notable achievements include the ground-shaking triumph of ENHERTU, eye-popping investments like Pfizer’s monumental $43 billion acquisition of Seagen, and the FDA’s greenlight for ELAHERE. These milestones have transformed the ADC landscape, driving increased interest and investment in the field, which now has a preclinical and clinical arena dynamically evolving.
As such, the 14th World ADC London returns next March. This will be the first opportunity in the new year to explore these monumental wins, reflect on ongoing challenges, and collaborate on innovative strategies to supercharge all stages of ADC development.
Secure regulatory approvals and position ADCs at the forefront of revolutionary therapies with exclusive insights into linker-payload optimization, pioneering target discovery, strategic toxicity management, precise combination partner selection, and rapid manufacturing advancements.
No ADC stone was left unturned as we united 600+ leading players in the field under one roof including AbbVie, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Immunogen, Regeneron, Seagen, and many more.